Efficacy and Acceptability of a New Water-Soluble Nail Strengthener Containing
Brittle nails
Keratin
Nail fragility
Therapy
Weak nails
Journal
Skin appendage disorders
ISSN: 2296-9195
Titre abrégé: Skin Appendage Disord
Pays: Switzerland
ID NLM: 101670617
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
25
11
2019
accepted:
03
12
2019
entrez:
8
4
2020
pubmed:
8
4
2020
medline:
8
4
2020
Statut:
ppublish
Résumé
Brittle nail syndrome is characterized by dry, weak, easily breakable nails that show inelasticity, splitting and overall nail plate fragility. This paper describes in vitro and clinical studies using bovine hooves designed to assess the efficacy, compatibility and acceptability of a water-soluble nail strengthener (WSNS), containing In the in vitro study, the WSNS was tested versus placebo and a marketed product on bovine hoof membranes, applied once daily for 14 days for evaluation of firmness, viscoelasticity and thickness before and after applications. In a clinical study, 23 female subjects affected by brittle nails were included, and the WSNS was applied once daily for 3 months. Signs and symptoms were rated by the investigators and by the participants during treatment at 28 and 84 days with different methods and dermoscopic images. Subjective efficacy was evaluated by specific questionnaires. In the in vitro study, the daily application of the WSNS and marketed product led to a significant increase in firmness index. In the clinical study, the nails on the treated hand presented an improvement in nail appearance and weakness, after 28 and 84 days of WSNS application, respectively. The nails not treated showed no improvement. The WSNS was well tolerated. The WSNS containing
Identifiants
pubmed: 32258054
doi: 10.1159/000505217
pii: sad-0006-0108
pmc: PMC7109389
doi:
Types de publication
Journal Article
Langues
eng
Pagination
108-114Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
Corinne Granger, S. Aladren and M. Narda declare that they are employed by ISDIN. The other authors declare that they have no conflict of interest.
Références
Aging (Milano). 2001 Apr;13(2):131-8
pubmed: 11405386
J Am Acad Dermatol. 1991 Jan;24(1):44-8
pubmed: 1999528
Int J Dermatol. 2019 Mar;58(3):311-318
pubmed: 30246242
Clin Dermatol. 2013 Sep-Oct;31(5):578-86
pubmed: 24079587
Dermatol Ther (Heidelb). 2020 Feb;10(1):15-27
pubmed: 31749091
Eur J Dermatol. 2002 Mar-Apr;12(2):119-28
pubmed: 11872405
Indian J Dermatol Venereol Leprol. 2005 Nov-Dec;71(6):386-92
pubmed: 16394478
J Am Acad Dermatol. 1990 Dec;23(6 Pt 1):1127-32
pubmed: 2273113
Drug Dev Ind Pharm. 2005 Jan;31(1):11-7
pubmed: 15704853
J Cosmet Dermatol. 2004 Jul;3(3):138-44
pubmed: 17134428
Eur J Pharm Sci. 2003 Nov;20(3):319-25
pubmed: 14592697
Dermatol Ther (Heidelb). 2020 Feb;10(1):119-131
pubmed: 31749090
Pharm Res. 2001 Oct;18(10):1468-71
pubmed: 11697474
Dermatol Clin. 2015 Apr;33(2):175-83
pubmed: 25828710
Semin Dermatol. 1991 Mar;10(1):21-5
pubmed: 2018715
Dermatologica. 1986;172(3):144-7
pubmed: 3699216
Clin Cosmet Investig Dermatol. 2014 May 27;7:185-90
pubmed: 24904219
Arch Histol Cytol. 2006 Dec;69(5):323-8
pubmed: 17372388
Cutis. 1993 Apr;51(4):303-5
pubmed: 8477615
J Cosmet Dermatol. 2004 Jul;3(3):131-7
pubmed: 17134427
J Am Acad Dermatol. 2005 Oct;53(4):644-51
pubmed: 16198786
Dermatol Clin. 1985 Jul;3(3):421-9
pubmed: 2420499
Arch Dermatol Forsch. 1971;240(4):349-64
pubmed: 4103487